Working… Menu

A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01144351
Recruitment Status : Terminated
First Posted : June 15, 2010
Last Update Posted : December 14, 2015
Information provided by (Responsible Party):
Elan Pharmaceuticals

Brief Summary:
The purpose of this study is to determine the safety and tolerability of ELND002 in patients with relapsing forms of secondary progressive multiple sclerosis (SPMS) or relapsing-remitting multiple sclerosis (RRMS).

Condition or disease Intervention/treatment Phase
Multiple Sclerosis Drug: ELND002 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Study Start Date : March 2010
Actual Primary Completion Date : December 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: ELND002
ELND002 sc injection
Drug: ELND002
Placebo Comparator: Placebo
placebo injection
Drug: Placebo

Primary Outcome Measures :
  1. To determine the safety and tolerability of ELND002 including the identification of dose-limiting toxicity(ies) (DLT) and determination of the maximum tolerated dose (MTD) in patients with multiple sclerosis (MS). [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Assessment of PK and PD measures of ELND002 (including but not limited to Cmax, Tmax, T1/2, AUC) [ Time Frame: 12 weeks ]
    Measurement of drug concentration, alpha 4 receptor saturation, soluble VCAM and MADCAM.

  2. Assessment of the cumulative number and volume of Gd-enhancing T1-weighed MRI brain lesions [ Time Frame: 12 weeks ]
  3. Reduction in rate of clinical relapses. [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Has either clinically definite or laboratory-supported definite relapsing forms of MS for at least 2 years
  • Patients with SPMS or RRMS have documented medical history of relapse in the past year or MRI-documented evidence of MS activity in the past year
  • Has had an inadequate response or intolerability to interferon and/or glatiramer acetate
  • Is able and willing to undergo Gd administration and repeat MRI testing

Exclusion Criteria:

  • Has primary progressive MS (PPMS)
  • Any history of treatment with recombinant humanized monoclonal antibodies
  • Has received treatment with immunosuppressant medications or experimental agents within 3 months prior to the Baseline
  • A history of opportunistic infection or the presence of any active infection within 3 months prior to Baseline
  • Any history of congestive heart failure or currently has a pacemaker
  • Has a known or suspected hypersensitivity to sulfonamides or any of the components of the investigational drug
  • Has any medical history or psychiatric condition that would impact outcome or study participation
  • Has other clinically significant abnormality on physical, neurological, laboratory, or ECG examination as listed in the protocol during the Screening Phase

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01144351

Layout table for location information
United States, California
Research Site
Berkeley, California, United States, 94705
Research Site
Fresno, California, United States, 93710
Research Site
Newport Beach, California, United States, 92663
United States, Colorado
Research Site
Aurora, Colorado, United States, 80045
United States, Florida
Research Site
Tampa, Florida, United States, 33609
Research Site
Vero Beach, Florida, United States, 32960
United States, Illinois
Research Site
Northbrook, Illinois, United States, 60062
United States, Michigan
Research Site
Farmington Hills, Michigan, United States, 48334
United States, Minnesota
Research Site
Minneapolis, Minnesota, United States, 55404
United States, New Mexico
Research Site
Albuquerque, New Mexico, United States, 87106
United States, North Carolina
Research Site
Raleigh, North Carolina, United States, 27607
United States, Ohio
Research Site
Cincinnati, Ohio, United States, 45219
Research Site
Uniontown, Ohio, United States, 44685
United States, Tennessee
Research Site
Cordova, Tennessee, United States, 78258
Research Site
Knoxville, Tennessee, United States, 37920
United States, Texas
Research Site
San Antonio, Texas, United States, 78258
United States, Utah
Research Site
Salt Lake City, Utah, United States, 84106
Canada, Alberta
Research Site
Calgary, Alberta, Canada, T2N 2T9
Canada, Quebec
Research Site
Greenfield Park, Quebec, Canada, J4V 2J2
Research Site
Montreal, Quebec, Canada, H3A 2B4
Sponsors and Collaborators
Elan Pharmaceuticals
Layout table for additonal information
Responsible Party: Elan Pharmaceuticals Identifier: NCT01144351    
Other Study ID Numbers: ELND002-MS103
First Posted: June 15, 2010    Key Record Dates
Last Update Posted: December 14, 2015
Last Verified: December 2015
Keywords provided by Elan Pharmaceuticals:
Relapsing Forms of Secondary Progressive Multiple Sclerosis (SPMS)
or Relapsing-Remitting Multiple Sclerosis (RRMS)
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases